The CWRU Cancer Center Flow Cytometry resource is an established core that has a history of stable direction (Director: 15 years), management (6 & 7 years), NCI funding (13 years), and supporting cancer research with up-to-date, well-maintained flow cytometry and cell sorting instrumentation. The director, James Jacobberger, has a major interest in the science of Cytometry. Considered to be one of the field?s leaders, Dr. Jacobberger has a strong commitment to developing and maintaining a robust and sophisticated Flow Cytometry Core that is especially flexible and can respond to the diverse needs of the CWRU Cancer Center investigators. The manager, Mr. Sramkoski, is a trained Medical Technician, with specialization in Cytometry who is equally committed. Together they have 37 years experience in the field and provide a superior level of expertise and guidance during experimental design and protocol development. Use of the core has grown steadily for 15 years with an especially sharp increase in recent years. In any one year there are approximately 70 principal investigators (users) drawn from a base of approximately 127 active investigators who have used the facility within the first few years. (Since inception, the core has assisted 167 investigators.) The facility currently operates at full capacity with two instruments - a single laser 4 color analyzer and a 4 laser, 4 color, 6 parameter cell sorter. An order has been placed for a new Becton-Dickinson LSR analyzer with 3 lasers and 6 color capability. A grant has been submitted for an additional (high speed) cell sorter that will have 5 lasers and 8 color capacity. Acquisition of these instruments will ensure that the facility can continue to support growth of cancer research at CWRU. Since the last competitive renewal an Assistant Manager has been hired to handle the increased work load and to establish a staining service. The facility operates with planned development that does and will provide outstanding technology and science in Cytometry for the Cancer Center?s membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-14
Application #
6658305
Study Section
Project Start
2002-09-13
Project End
2003-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
14
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications